CoDa Therapeutics Closes B Round with $40 Million from Rusnano/ Domain-Led Syndicate
This article was originally published in The Pink Sheet Daily
Executive Summary
Wound healing company CoDa Therapeutics is the first Domain portfolio company to benefit from the venture capital firm’s new, $760 million partnership with Russian sovereign fund Rusnano
You may also be interested in...
Regado Snags $51M From Venture Funding Led By Rusnano
New Jersey biotech Regado Biosciences raised $51 million in a Series E offering led by Russian investment group Rusnano. The money will be used to initiate a Phase III trial of its anticoagulant REG1.
Deals Of The Week: Merck/Chimerix, Merck/Yamasa, CoDa/Rusnano/Domain
AstraZeneca has done a good job of preparing investors for revenue declines due to its patent cliff, but Wall Street thinks the pharma will need to undertake significant M&A activity to remain viable.
Financings Of The Fortnight: Bluebird Spots Brighter Skies For Gene Therapy Investment
Plus news on recent financings by California Institute for Regenerative Medicine, Alimera Sciences, Durata Therapeutics and CoDa Therapeutics.